Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 27, 2020

Primary Completion Date

November 9, 2021

Study Completion Date

May 2, 2024

Conditions
CD55-deficient Protein-losing EnteropathyCHAPLE
Interventions
DRUG

Pozelimab

Single loading intravenous (IV) dose on day 1, then fixed doses sub-cutaneous (SC) (based on body weight) QW (±2 days) over the treatment period.

Trial Locations (3)

10330

Regeneron Research Site, Pathum Wan

20892

Regeneron Research Site, Bethesda

34890

Regeneron Research Site, Istanbul

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY